I think I agree with Pfizer here.
Any company would jump at a chance to make billions off of a working Alzheimer’s drug.
There’ve been several widely publicized drugs that hit the market for testing that promptly failed (and hurt the company financially in the process) that Pfizer taking a conservative approach may have been prudent.
I don’t like taking drugs and try to stay off them. But I might rethink it it since I could probably qualify due to a psoriasis patch on my leg.